Marker Therapeutics Inc (MRKR) — Institutional Investor Activity (Q2 2026)

MRKR ranks #7097 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

MRKR is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

35 institutions disclose a position in MRKR, but none treat it as a major bet — even NEA Management Company, LLC, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

MRKR reported a net loss of $8.7M over the trailing twelve months.

• Not yet profitable — net loss of $8.7M over the trailing twelve months
• Revenue grew 3.5% year over year
• Net income improved year over year, from -$14.6M to -$8.7M
• Operating cash flow was negative, using $12.0M in cash
• Current ratio of 8.39x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.14x equity — within a conventional range